Information about trial data of Johnson & Johnson’s one-dose Covid-19 vaccine (vaccine called Ad26.COV2.S) was published in the New England Journal of Medicine on January 13.

J&J scientists randomly injected healthy adult volunteers between the ages of 18 and 55 and 65 and older with high or low doses of Ad26.COV2.S or placebo.

According to trial data, most volunteers produced neutralizing antibodies.

The most common side effects are fever, fatigue, headache, muscle pain, and pain at the injection site.

Johnson & Johnson’s Covid-19 vaccine in the laboratory.

In an interview with CNBC, Dr. Paul Stoffels, chief scientific officer at J&J, said phase one and two clinical trial data showed that a single shot of the vaccine `produces durable antibodies.`

The trial tested 805 volunteers.

Unlike some other Covid-19 vaccines that require two doses about 3-4 weeks apart, Johnson & Johnson’s (J&J) vaccine only requires one dose, reducing the logistical burden on service providers.

US officials and Wall Street analysts predict J&J’s vaccine could be authorized as early as February. Public health officials and infectious disease experts said, world leaders

If J&J’s vaccine is approved by the US Food and Drug Administration, this will be the third vaccine approved for use in the US.

US officials complain that the pace of vaccination is too slow because demand for vaccines exceeds supply.

The US Department of Health and Human Services reached an agreement with Janssen, a subsidiary of J&J pharmaceuticals, worth about one billion USD for 100 million vaccine doses in August 2020.

Dr. Paul Stoffels, Chief Scientific Officer at J&J, added that the company plans to ship the vaccine at a temperature of 2-8 degrees Celsius, which is about 36-46 degrees Fahrenheit.